Compare CARS & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | FDMT |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.9M | 695.3M |
| IPO Year | 2017 | 2019 |
| Metric | CARS | FDMT |
|---|---|---|
| Price | $10.42 | $14.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $16.00 | ★ $31.71 |
| AVG Volume (30 Days) | 485.6K | ★ 775.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $723,239,000.00 | $85,209,000.00 |
| Revenue This Year | $3.03 | N/A |
| Revenue Next Year | $2.57 | $70.28 |
| P/E Ratio | $33.03 | ★ N/A |
| Revenue Growth | 0.57 | ★ 230194.60 |
| 52 Week Low | $7.40 | $6.96 |
| 52 Week High | $13.69 | $16.93 |
| Indicator | CARS | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 50.82 |
| Support Level | $9.21 | $13.30 |
| Resistance Level | $11.68 | $15.29 |
| Average True Range (ATR) | 0.39 | 0.87 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 24.17 | 42.55 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).